COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article Access statistics

Viewed: 615

Emailed: 0

PDF Downloaded: 299

International Journal of Pharmaceutical Chemistry and Analysis

Current perspective of histone deacetylase inhibitors: A review

Full Text PDF Share on Facebook Share on Twitter

Author Details : Bhavini K Gharia*, Jagatkumar Upadhyay, Bhanubhai N Suhagia, Shailesh A Shah

Volume : 5, Issue : 3, Year : 2018

Article Page : 108-122

Suggest article by email


Epigenetic therapeutics are the new generation of chemotherapeutics for treatment of cancer, and histone deacetylase inhibitors have been actively discovered in this category They target the biological processes including the cell cycle, apoptosis, DNA repair, cell cycle control, autophagy, metabolism, senescence and chaperone function. Several families of histone deacetylase (HDAC) inhibitors have been synthesized and evaluated. Their positive effects on the cell cycle have been demonstrated in biological models and in clinical trials. Recently Food and Drug Administration has approved Vorinostat, Romidepsin and Belinostat for oncologic indications of refractory cutaneous and peripheral T cell Lymphoma. These advances have provided the motivation to develop more potent and selective inhibitors and target other pathologic conditions with these drugs. Major ongoing efforts are to develop inhibition as monotherapy, rational combination with chemotherapy and other targeted drugs. Some progress is made into developing isoform specific drugs. In this perspective, the biological functions and potential substrates of histone deacetylase enzymes are reviewed and the characteristics of this inhibitors are discussed in respect with anticancer activity and further therapeutic interest.

Keywords: Epigenetic therapeutics, Histone deacetylase inhibitors, Anticancer, Classification, Food and drug administration approved drugs.

Doi : 10.18231/2394-2797.2018.0018

How to cite : Gharia B K, Upadhyay J, Suhagia B N, Shah S A, Current perspective of histone deacetylase inhibitors: A review. Int J Pharm Chem Anal 2018;5(3):108-122

Copyright © 2018 by author(s) and Int J Pharm Chem Anal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (